Maquet Recall: Bleeding Risk Cited for Tiger Paw Heart Staple

Medical device lawyers note a March 25, 2015 recall of over 4,000 Tiger Paw System II surgical heart staples due to bleeding risks. The U.S. Food and Drug Administration has designated the recall as Class 1, which is the most serious type of recall and involves “situations in which there is a reasonable probability that use of these products will cause serious adverse health consequences or death.” Maquet Medical Systems, which initiated the recall, has described the situation as “urgent.”

If you are the recipient of a Tiger Paw heart staple and would like more information about the recall and your options, contact Attorney Group today. We offer free, no obligation consultations, and if you decide to pursue a legal claim we can connect you with an affiliated medical device recall lawyer who can assist you through the legal process. The time to pursue a claim is limited, so contact us today.

What is the Tiger Paw Heart Staple?

The Tiger Paw System II surgical staple is a medical device that is used to close tissue in the left atrial appendage of the heart during heart surgery. The purpose of the device is to reduce the risk of postoperative stroke caused by atrial fibrillation.

The device is manufactured by LAAx, Inc., which was acquired by Maquet Cardiovascular LLC in 2013. In a press release announcing the acquisition, Maquet described the Tiger Paw II system as:

[A]n implantable LAA occlusion device featuring an exceptionally soft silicone fastener that conforms to the appendage anatomy and tissue thickness, spreading the pressure equally. With its simple and reliable application, TigerPaw II is the only device currently available that has been proven 100-percent occlusive of the LAA during cardiac surgery.

Maquet, which initiated the recall, describes itself as “the global leader in providing medical systems that meet the needs of the most medically challenging patients, while exceeding the expectations of the hospital teams that care for them.”

The Maquet recall applies to 4,154 units of the Tiger Paw System II device distributed between April 2013 and March 23, 2105. The company received 51 reports of adverse events related to the device, including one death.

Injured Patients May Be Entitled to Compensation

Patients who have been injured by defective medical devices may be entitled to recover compensation for medical expenses, lost wages, pain and suffering, and any long-term, permanent disability that results from their injuries. Families of those who have died as a result of injuries or complications may be able to recover compensation for the wrongful death of their loved one, including mental anguish and loss of financial support.

Because the legal issues involved in pursuing a claim against the manufacturer of a defective medical device or other product are complicated, affected patients and their families are encouraged to seek the advice of an attorney.

The Time to Pursue a Claim is Limited. Contact Us Today.

If you would like more information about the Maquet recall or about pursuing a claim against a defective device manufacturer, contact Attorney Group today.

You can either fill out a form on this page by clicking the Free Case Evaluation Button below, call us at the number listed above, or email us at info@attorneygroup.com. We have representatives available to speak with you 24 hours a day. After you contact us, an attorney will follow up with you to learn more about your case. Your consultation will be free and confidential, and there is no obligation on your part after you speak with us.

If you choose to pursue a claim, an affiliated attorney will work with you to help you through the legal process. You will not pay any fees or costs unless a recovery is obtained on your behalf, in which case fees and costs will be deducted from the amount recovered. You will not be required to pay any money out of pocket to pursue a claim. However, state laws limit the time that you have to bring a claim for compensation, so contact us today.

Comments